Share

In This Section

FDA Approves Dabrafenib + trametinib for Pediatric Patients with LGG

On March 16, 2023, the U.S Food and Drug Administration (FDA) approved dabrafenib with trametinib for pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.

For more information read the FDA announcement and the Novartis announcement.

Posted 3/20/2023